XML 71 R43.htm IDEA: XBRL DOCUMENT
v3.25.2

ACQUISITION - Narrative (Details) $ / shares in Units, $ in Thousands | 5 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | ---
Mar. 31, 2024 CAD ($) | Mar. 31, 2025 CAD ($) | Mar. 31, 2024 CAD ($) | Oct. 23, 2023 shares patent_family patent application $ / shares | Feb. 28, 2023 CAD ($)
Disclosure of detailed information about business combination [line items] |  |  |  |  |
Net loss for the year |  | $ (113,137) | $ (78,080) |  |
Small Pharma Inc. ("Small Pharma") |  |  |  |  |
Disclosure of detailed information about business combination [line items] |  |  |  |  |
Ratio of common shares issued |  |  |  | 0.634% |
Number of instruments or interests issued or issuable (in shares) | shares |  |  |  | 2,130,138 |
Unexercised stock options in subsidiary, compensation for cancellation (in CAD per share) | $ / shares |  |  |  | $ 0.001 |
Number of active patent families | patent_family |  |  |  | 17 |
Number of pending patent applications | application |  |  |  | 92 |
Number of granted patents | patent |  |  |  | 30 |
Net loss for the year | $ (1,666) |  |  |  |
Small Pharma Inc. ("Small Pharma") | Canada |  |  |  |  |
Disclosure of detailed information about business combination [line items] |  |  |  |  |
Loss carryforwards |  |  |  |  | $ 9,393
Small Pharma Inc. ("Small Pharma") | United Kingdom |  |  |  |  |
Disclosure of detailed information about business combination [line items] |  |  |  |  |
Loss carryforwards |  |  |  |  | $ 46,631

X
- Definition Number Of Active Patent Families + References No definition available. + Details
Name: | cybn_NumberOfActivePatentFamilies
Namespace Prefix: | cybn_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Granted Patents + References No definition available. + Details
Name: | cybn_NumberOfGrantedPatents
Namespace Prefix: | cybn_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Pending Patent Applications + References No definition available. + Details
Name: | cybn_NumberOfPendingPatentApplications
Namespace Prefix: | cybn_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Ratio Of Common Shares Issued To Every One Share Of Subsidiary Outstanding + References No definition available. + Details
Name: | cybn_RatioOfCommonSharesIssuedToEveryOneShareOfSubsidiaryOutstanding
Namespace Prefix: | cybn_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Unexercised Stock Options In Subsidiary, Compensation For Cancellation + References No definition available. + Details
Name: | cybn_UnexercisedStockOptionsInSubsidiaryCompensationForCancellation
Namespace Prefix: | cybn_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 12 -IssueDate 2024-01-01 -Paragraph 81 -Subparagraph g -Clause i -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_g_i&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_DeferredTaxLiabilityAsset
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfBusinessCombinationsLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of instruments or interests issued or issuable at acquisition date for equity interests of the acquirer transferred as consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 3 -IssueDate 2024-01-01 -Paragraph B64 -Subparagraph f -Clause iv -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B64_f_iv&doctype=Appendix&subtype=B -URIDate 2024-03-27 + Details
Name: | ifrs-full_NumberOfInstrumentsOrInterestsIssuedOrIssuable
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | instant

X
- Definition The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 7 -IssueDate 2024-01-01 -Paragraph 18 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_18_b&doctype=Standard -URIDate 2024-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 1 -IssueDate 2024-01-01 -Paragraph 32 -Subparagraph a -Clause ii -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_32_a_ii&doctype=Standard -URIDate 2024-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 1 -IssueDate 2024-01-01 -Paragraph 24 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_24_b&doctype=Standard -URIDate 2024-03-27 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2024-01-01 -Paragraph 28 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_b&doctype=Standard -URIDate 2024-03-27 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2024-01-01 -Paragraph 23 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23&doctype=Standard -URIDate 2024-03-27 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Name IFRS -Number 12 -IssueDate 2024-01-01 -Paragraph B10 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B -URIDate 2024-03-27 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Name IFRS -Number 17 -IssueDate 2024-01-01 -Paragraph 113 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_113_b&doctype=Standard -URIDate 2024-03-27 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 81A -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81A_a&doctype=Standard -URIDate 2024-03-27 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2024-01-01 -Paragraph 106 -Subparagraph d -Clause i -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d_i&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_ProfitLoss
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=cybn_SmallPharmaInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=country_CA
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=country_GB
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |